Gastric

Gastric
2025-08-14T00:00:00.000+10:00
Ongoing

HLX22-GC-301

HLX22-GC-301
Gastric

A Randomized, Double-blinded, Multicentre, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

A Randomized, Double-blinded, Multicentre, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer.

Trial overview

Clinical Area

Medical Oncology

Disease

Gastric

Disease site

Gastroinstestinal

Study Phase

III

Trial Identifiers

Registration number: NCT06532006

https://clinicaltrials.gov/study/NCT06532006

GenesisCare Location(s)
Principal Investigator(s)
Medical Oncologist

A/Prof. Stephanie Lim

MBBS, FRACP, PhD, BMedSci

A/Prof. Stephanie Lim
location pin icon

Campbelltown (Oncology)

View Profile
Profile Image - A/Prof. Stephanie  Lim

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.